Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Atara Biotherapeutics (ATRA) Gross Margin (2022 - 2025)

Historic Gross Margin for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to 96.67%.

  • Atara Biotherapeutics' Gross Margin rose 155800.0% to 96.67% in Q3 2025 from the same period last year, while for Sep 2025 it was 81.63%, marking a year-over-year decrease of 10700.0%. This contributed to the annual value of 83.71% for FY2024, which is 873600.0% up from last year.
  • Per Atara Biotherapeutics' latest filing, its Gross Margin stood at 96.67% for Q3 2025, which was up 155800.0% from 96.85% recorded in Q2 2025.
  • Atara Biotherapeutics' 5-year Gross Margin high stood at 100.0% for Q1 2022, and its period low was 202.51% during Q2 2023.
  • For the 4-year period, Atara Biotherapeutics' Gross Margin averaged around 59.52%, with its median value being 83.84% (2024).
  • Per our database at Business Quant, Atara Biotherapeutics' Gross Margin crashed by -3025100bps in 2023 and then soared by 2863500bps in 2024.
  • Atara Biotherapeutics' Gross Margin (Quarter) stood at 100.0% in 2022, then crashed by -74bps to 25.68% in 2023, then surged by 209bps to 79.25% in 2024, then increased by 22bps to 96.67% in 2025.
  • Its Gross Margin stands at 96.67% for Q3 2025, versus 96.85% for Q2 2025 and 79.18% for Q1 2025.